EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

Judith S Currier iD, Carlee Moser iD, Joseph J Eron, Kara W Chew, Davey M Smith, Arzhang Cyrus Javan, David Alain Wohl, Eric S Daar, Michael D Hughes, ACTIV-2/A5401 Study Team

The Journal of Infectious Diseases · 31.08.2023 · 228 (Supplement_2) · S77-S82

DOI: 10.1093/infdis/jiad246 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 31.08.2023. Verfasst von Judith S Currier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical Trials Registration ClinicalTrials.gov Identifier: NCT04518410.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 Drug TreatmentAntiviral AgentsHumansOutpatients

Stichwörter der Autor:innen

ACTIV-2COVID-19clinical trialmonoclonal antibodies

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA.
  • Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Medicine, University of California, San Diego, La Jolla, California, USA.
  • Division of AIDS, National Institutes of Health, Rockville, Maryland, USA.
  • Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.

ORCID-Profile: Judith S Currier, Carlee Moser

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Currier, J. S., Moser, C., Eron, J. J., Chew, K. W., Smith, D. M., Javan, A. C., Wohl, D. A., Daar, E. S., Hughes, M. D., & ACTIV-2/A5401 Study Team (2023). ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. The Journal of Infectious Diseases, 228(Supplement_2), S77-S82. https://doi.org/10.1093/infdis/jiad246

Vancouver

Currier JS, Moser C, Eron JJ, Chew KW, Smith DM, Javan AC, et al. ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. The Journal of Infectious Diseases. 2023;228(Supplement_2):S77-S82. doi:10.1093/infdis/jiad246

BibTeX
@article{Currier2023,
  author = {Currier, Judith S and Moser, Carlee and Eron, Joseph J and Chew, Kara W and Smith, Davey M and Javan, Arzhang Cyrus and Wohl, David Alain and Daar, Eric S and Hughes, Michael D and ACTIV-2/A5401 Study Team, ACTIV-2/A5401 Study Team},
  title = {ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  volume = {228},
  number = {Supplement_2},
  pages = {S77--S82},
  doi = {10.1093/infdis/jiad246}
}
Kostenlos starten →